Which has higher valuation & earnings, LENZ or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENZ Therapeutics $19.09M 8.56 -$82.13M -$3.60 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Does the media prefer LENZ or ATHE?

In the previous week, LENZ Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 4 mentions for Alterity Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, AARD or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is AARD or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -61.71% -56.29% Alterity Therapeutics N/A N/A N/A

Does the media prefer AARD or ATHE?

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 4 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.67 beat Alterity Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MENS or ATHE?

Alterity Therapeutics has a consensus target price of $10.00, indicating a potential upside of 112.77%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation & earnings, MENS or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is MENS or ATHE more profitable?

Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Alterity Therapeutics N/A N/A N/A

Which has stronger valuation & earnings, ATHE or CRDL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.28 N/A

Is ATHE or CRDL more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Cardiol Therapeutics N/A -229.43% -165.60%

Does the media refer more to ATHE or CRDL?

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 4 articles in the media. Alterity Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, MIST or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Milestone Pharmaceuticals $1.55M 102.01 -$63.06M -$0.68 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is MIST or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -339.33% -61.79% Alterity Therapeutics N/A N/A N/A

Does the media favor MIST or ATHE?

In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 4 articles in the media. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Alterity Therapeutics (ATHE) Competitors

$4.70 +0.15 (+3.30%)

Closing price 03:59 PM Eastern

Extended Trading

$4.77 +0.07 (+1.47%)

As of 05:50 PM Eastern

Compare

ATHE vs. LENZ, AARD, MENS, CRDL, and MIST

Should you buy Alterity Therapeutics stock or one of its competitors? Alterity Therapeutics's main competitors and comparable companies include LENZ Therapeutics (LENZ), Aardvark Therapeutics (AARD), Jyong Biotech (MENS), Cardiol Therapeutics (CRDL), and Milestone Pharmaceuticals (MIST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alterity Therapeutics compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

LENZ Therapeutics currently has a consensus price target of $29.80, indicating a potential upside of 471.98%. Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 112.77%. Given LENZ Therapeutics' higher possible upside, equities analysts plainly believe LENZ Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

LENZ Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Alterity Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. Alterity Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Alterity Therapeutics	N/A	N/A	N/A

In the previous week, LENZ Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for LENZ Therapeutics and 4 mentions for Alterity Therapeutics. LENZ Therapeutics' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.56	-$82.13M	-$3.60	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

LENZ Therapeutics and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Aardvark Therapeutics presently has a consensus target price of $16.30, suggesting a potential upside of 126.70%. Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 112.77%. Given Aardvark Therapeutics' higher possible upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 4 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.67 beat Alterity Therapeutics' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Alterity Therapeutics	N/A	N/A	N/A

Aardvark Therapeutics has a beta of 3.8, suggesting that its stock price is 280% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

2.1% of Alterity Therapeutics shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Summary

Alterity Therapeutics beats Aardvark Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Alterity Therapeutics has a consensus target price of $10.00, indicating a potential upside of 112.77%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Jyong Biotech has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

2.1% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alterity Therapeutics had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Alterity Therapeutics and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Jyong Biotech	Neutral
Alterity Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats Jyong Biotech on 6 of the 8 factors compared between the two stocks.

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 4 articles in the media. Alterity Therapeutics' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Alterity Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.43%	-165.60%

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alterity Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Alterity Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 112.77%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 466.67%. Given Cardiol Therapeutics' higher probable upside, analysts clearly believe Cardiol Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Alterity Therapeutics beats Cardiol Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Alterity Therapeutics compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Milestone Pharmaceuticals presently has a consensus target price of $7.25, suggesting a potential upside of 470.87%. Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 112.77%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Milestone Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Milestone Pharmaceuticals and Milestone Pharmaceuticals both had 4 articles in the media. Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	102.01	-$63.06M	-$0.68	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Alterity Therapeutics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Alterity Therapeutics	N/A	N/A	N/A

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Milestone Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Summary

Milestone Pharmaceuticals beats Alterity Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHE vs. The Competition

Export

Metric	Alterity Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$41.69M	$11.87B	$6.99B	$12.83B
Dividend Yield	N/A	2.69%	2.58%	10.06%
P/E Ratio	N/A	783.49	268.64	24.76
Price / Sales	N/A	748.17	585.26	96.30
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	1.52	10.16	11.31	6.45
Net Income	-$7.87M	$2.78B	$3.44B	$347.05M
7 Day Performance	7.06%	0.90%	2.25%	0.98%
1 Month Performance	-13.44%	-1.48%	-0.25%	-0.64%
1 Year Performance	-11.65%	182.35%	76.14%	22.27%

Alterity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHE Alterity Therapeutics	3.1802 of 5 stars	$4.70 +3.3%	$10.00 +112.8%	-15.1%	$41.69M	N/A	N/A	10	Analyst Forecast
LENZ LENZ Therapeutics	2.0151 of 5 stars	$5.05 +1.2%	$29.80 +490.1%	-84.5%	$156.62M	$19.09M	N/A	110	News Coverage Earnings Report
AARD Aardvark Therapeutics	3.5529 of 5 stars	$7.27 +2.7%	$16.30 +124.2%	-36.9%	$154.94M	N/A	N/A	18	News Coverage Earnings Report
MENS Jyong Biotech	N/A	$2.04 +2.0%	N/A	-95.4%	$152.05M	N/A	N/A	31	Gap Up
CRDL Cardiol Therapeutics	2.2483 of 5 stars	$1.36 +3.8%	$8.50 +525.0%	+49.1%	$151.81M	N/A	N/A	20	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alterity Therapeutics (ATHE) Competitors

ATHE vs. LENZ, AARD, MENS, CRDL, and MIST

How does Alterity Therapeutics compare to LENZ Therapeutics?

Summary

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Summary

How does Alterity Therapeutics compare to Jyong Biotech?

Summary

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Summary

How does Alterity Therapeutics compare to Milestone Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alterity Therapeutics (ATHE) Competitors

ATHE vs. LENZ, AARD, MENS, CRDL, and MIST

How does Alterity Therapeutics compare to LENZ Therapeutics?

Do analysts recommend LENZ or ATHE?

Which has more risk and volatility, LENZ or ATHE?

Is LENZ or ATHE more profitable?

Does the media prefer LENZ or ATHE?

Which has higher valuation & earnings, LENZ or ATHE?

Do insiders and institutionals believe in LENZ or ATHE?

Summary

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Do analysts rate AARD or ATHE?

Does the media prefer AARD or ATHE?

Is AARD or ATHE more profitable?

Which has more risk & volatility, AARD or ATHE?

Do insiders and institutionals hold more shares of AARD or ATHE?

Which has stronger valuation and earnings, AARD or ATHE?

Summary

How does Alterity Therapeutics compare to Jyong Biotech?

Which has better valuation & earnings, MENS or ATHE?

Do analysts prefer MENS or ATHE?

Which has more volatility & risk, MENS or ATHE?

Do institutionals & insiders believe in MENS or ATHE?

Does the media prefer MENS or ATHE?

Is MENS or ATHE more profitable?

Summary

How does Alterity Therapeutics compare to Cardiol Therapeutics?

Does the media refer more to ATHE or CRDL?

Which has stronger valuation & earnings, ATHE or CRDL?

Is ATHE or CRDL more profitable?

Do insiders & institutionals hold more shares of ATHE or CRDL?

Which has more volatility and risk, ATHE or CRDL?

Do analysts prefer ATHE or CRDL?

Summary

How does Alterity Therapeutics compare to Milestone Pharmaceuticals?

Do analysts prefer MIST or ATHE?

Does the media favor MIST or ATHE?

Which has stronger earnings and valuation, MIST or ATHE?

Is MIST or ATHE more profitable?

Do insiders and institutionals hold more shares of MIST or ATHE?

Which has more volatility & risk, MIST or ATHE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools